Awards and Recognitions - The company was awarded the "2022 Quality Innovation Award" by the Ningbo High-tech Zone Management Committee on May 6, 2023[1]. - The company received the "2022 Advanced Industrial Enterprise Silver Award" from the Meixu Street Office of Ningbo High-tech Zone in May 2023[1]. - The company was included in the "2022 Positive List of Ecological Environment Supervision and Law Enforcement" by the Ningbo Ecological Environment Bureau[1]. - The company obtained several new certifications, including quality management, environmental management, intellectual property management, and occupational health and safety management systems[1]. - The company has been acknowledged as a "specialized, refined, distinctive, and innovative" enterprise by the Ministry of Industry and Information Technology[45]. Financial Performance - The company's operating revenue for the current period is CNY 88,018,599.76, representing a year-on-year increase of 2.24%[19]. - The net profit attributable to shareholders of the listed company is CNY 28,409,612.23, reflecting a significant increase of 60.08% compared to the same period last year[19]. - The gross profit margin improved to 67.33%, up from 58.92% in the previous year[19]. - The total assets decreased by 7.29% to CNY 590,218,001.80 compared to the end of the previous year[20]. - The total liabilities decreased by 21.21% to CNY 44,842,706.02, indicating improved debt management[20]. - The net cash flow from operating activities increased by 26.25% to CNY 19,307,448.63[21]. - The company's operating profit increased by 17.73% to CNY 31,661,499.60, compared to CNY 26,893,156.99 in the same period last year[52]. - The company reported a total of CNY 7,102,907.80 in general risk reserves, which reflects a cautious approach to financial management[146]. Research and Development - The company has increased its R&D personnel by 46.81% in the first half of 2023, adding one national invention patent and three utility model patents[28]. - Research and development expenses increased by 33.70% to CNY 7,995,487.76, indicating a focus on innovation and product development[52]. - The company is focusing on self-research and development, increasing investment in R&D to protect its proprietary technologies through patent applications[71]. - The company aims to enhance its R&D capabilities and product innovation to meet customer demands and expand its product line, thereby strengthening its competitive advantage[69]. Market and Industry Trends - The domestic scientific instrument industry is in its early growth stage, with significant investment in technology innovation and talent development to catch up with international counterparts[32]. - The government has prioritized scientific instruments as a key development area, implementing policies to enhance innovation capabilities and support domestic enterprises[33]. - The life sciences instrument sector benefits from applications in various fields, including biomedicine, food safety, and environmental protection, driving technological advancements and scaling[34]. - The industry faces high technical barriers due to the complexity of R&D, requiring expertise in precision electronics, mechanics, and automation control[37]. - The market for scientific instruments is expanding, with domestic companies increasingly closing the gap with international leaders in terms of technology and product quality[32]. Operational Strategies - The company continues to focus on local service support capabilities, optimizing its sales team and combining online and offline marketing strategies[29]. - The company is focusing on enhancing its marketing network and local service capabilities, particularly in key regions such as the Yangtze River Delta and the Pearl River Delta[69]. - The company has established a stable and comprehensive marketing service network with 30 offices nationwide, providing professional services[45]. - The company is actively expanding its customer base and improving product technology and quality to increase product gross margins[70]. Shareholder and Governance - The company plans to repurchase between 2,400,000 and 3,800,000 shares, representing 2.62% to 4.15% of the total share capital, with a total estimated repurchase fund range of 26.4 million to 53.2 million RMB[79]. - The company has established a comprehensive internal control system to manage the use of raised funds effectively, ensuring compliance with relevant regulations[71]. - The company is working on improving its governance structure to reduce the concentration of control by major shareholders and enhance management effectiveness[70]. - The company has committed to fulfilling its public offering commitments without any violations as of the report date[84]. Cash Flow and Investments - The company's cash and cash equivalents decreased by 69.47% to ¥151,303,854.22, accounting for 25.64% of total assets[48]. - The company's trading financial assets increased significantly by 95,737.04% to ¥288,543,923.31, representing 48.89% of total assets[48]. - Cash flow from investment activities decreased by 717.78%, totaling -¥292,326,608.22, mainly due to the purchase of structured deposits[59]. - The net cash flow from investment activities was -CNY 273,160,723.33, worsening from -CNY 21,863,182.79 year-over-year[136]. Employee and Talent Management - The total number of employees increased from 293 to 342, representing a growth of approximately 16.7%[111]. - The number of technical staff rose from 47 to 69, an increase of 46.8%[111]. - The company has established a risk management strategy to address potential talent loss in the competitive life sciences instrument industry[69]. - The company plans to optimize its long-term incentive mechanisms to retain talent and align shareholder interests with company growth[114]. Legal and Compliance - There were no significant litigation or arbitration matters during the reporting period, indicating a stable legal environment for the company[75]. - The company has not experienced any significant changes in major risks during the reporting period, maintaining a stable risk profile[71]. - The company strictly adheres to its fundraising management system, with no violations or misappropriation of funds by major shareholders or actual controllers reported[99]. Financial Reporting and Accounting - The financial report was approved by the board of directors on August 22, 2023[153]. - The company has not made any changes to accounting policies or estimates compared to the previous year[151]. - The company consolidates financial statements for the entire corporate group, reflecting overall financial status, operating results, and cash flows[162].

证券代码：430685 证券简称：新芝生物 公告编号：2023-065 宁波新芝生物科技股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权现金管理情况 为提高闲置募集资金使用效率，公司第七届董事会第二十二次会议、第七 届监事会第十五次会议、2022 年第五次临时股东大会，审议通过了《关于使用 部分闲置募集资金进行现金管理的议案》，在确保资金安全、不影响募集资金 投资项目建设的前提下，拟使用额度不超过人民币 27,000 万元的闲置募集资 金进行现金管理，拟投资的产品须符合以下条件:（1）结构性存款、大额存单 等安全性高的保本型产品（; 2）流动性好,不得影响募集资金投资计划正常进行。 投资产品不得质押,产品专用结算账户(如适用)不得存放非募集资金或用作其 他用途,开立或注销产品专用结算账户的,公司应当及时报证券交易所备案并公 告。 具体内容详见公司在北京证券交易所信息披露平台（http://www.bse.cn/） 披露的《宁波新芝生 ...

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 说明会类型 宁波新芝生物科技股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日在北京证券交易所信息披露平台（http://www.bse.cn/）发布了《2022 年年度 报告》（公告编号：2023-025），为方便广大投资者更深入了解公司 2022 年度经 营业绩的具体情况，加强与投资者的互动交流，公司拟召开 2022 年年度报告 报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 5 月 5 日（星期五）15:00-17:00。 （二）会议召开地点 本次在全景网举办 2022 年度报告业绩说明会将采用网络远程方式召开， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 报告说明会 或 者 直 接 进 入 宁 波 新 芝 生 物 科 技 股 份 有 限 公 司 路 演 厅 （https://ir.p5w.net/c/430685.shtml）参与本次年度业绩说 ...

Financial Performance - Net profit attributable to shareholders for Q1 2023 was CNY 15,653,951.35, representing a significant increase of 122.85% year-over-year[10] - Operating revenue for Q1 2023 reached CNY 48,355,904.46, marking a growth of 40.88% compared to the same period last year[10] - Operating profit for Q1 2023 was CNY 23,917,267.22, compared to CNY 10,692,417.73 in Q1 2022, indicating an increase of about 123.5%[36] - Net profit for Q1 2023 was CNY 18,570,360.41, up from CNY 8,721,887.31 in Q1 2022, reflecting a growth of approximately 112.5%[36] - Basic earnings per share for Q1 2023 were CNY 0.17, compared to CNY 0.11 in Q1 2022, marking a 54.5% increase[36] - Total operating revenue for Q1 2023 reached CNY 48,355,904.46, a significant increase from CNY 34,323,159.94 in Q1 2022, representing a growth of approximately 40.9%[35] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 635,285,442.88, a decrease of 0.21% compared to the end of 2022[10] - Total liabilities decreased to CNY 28,881,772.31 in Q1 2023 from CNY 39,162,782.94 in Q1 2022, a reduction of approximately 26.3%[33] - The total liabilities to total assets ratio decreased to 6.87% from 8.94% year-over-year, indicating improved financial stability[10] - Total equity increased to CNY 554,482,021.79 in Q1 2023, compared to CNY 533,265,013.69 in Q1 2022, representing a growth of about 4.0%[33] - Total current assets amounted to ¥552,277,760.79, slightly down from ¥553,459,283.93 as of December 31, 2022, reflecting a decrease of approximately 0.2%[28] - Total liabilities decreased to ¥43,656,235.96 from ¥56,916,592.99, a reduction of approximately 23.3%[30] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 5,172,226.30, slightly worsening by 0.65% year-over-year[10] - Cash flow from operating activities showed a net outflow of ¥5,172,226.30, slightly worse than the outflow of ¥5,138,733.60 in Q1 2022[39] - Cash inflow from operating activities for Q1 2023 was $53,229,203.64, up from $40,066,632.51 in Q1 2022, representing a 32.5% increase[41] - Total cash outflow from operating activities in Q1 2023 was $62,554,911.79, compared to $45,866,225.11 in Q1 2022, an increase of 36.3%[41] - Investment activities resulted in a net cash outflow of ¥232,794,801.81, compared to a net inflow of ¥8,119,998.69 in Q1 2022[40] Shareholding Structure - The company reported a total shareholding of 51,892,798 shares, representing 56.70% of the total shares outstanding[20] - Major shareholders include Zhou Fang with 21,767,200 shares (23.79%), and Xiao Changjin with 14,486,500 shares (15.83%)[19] - The company has a total of 10 major shareholders, with the top three holding over 44% of the shares[19] - The shareholding structure indicates familial relationships among major shareholders, which may influence governance[20] Research and Development - Research and development expenses for Q1 2023 were CNY 3,304,808.87, up from CNY 2,839,218.06 in Q1 2022, indicating an increase of approximately 16.3%[35] - Research and development expenses increased to ¥2,772,658.63, compared to ¥2,348,390.43 in the same period last year, reflecting a 18% rise[37] Other Key Points - The company has no ongoing litigation or arbitration matters, and no external guarantees or loans were provided during the reporting period[23] - There were no significant related party transactions or other major transactions reported in the quarter[23] - The company confirmed that all previously disclosed commitments are being fulfilled without any breaches[24] - The financial report for the first quarter of 2023 has not been audited[27] - The company did not engage in any share buyback activities during the reporting period[23] - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[31] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[36]

Company Overview - Ningbo Scientz Biotechnology Co., Ltd. successfully listed on the Beijing Stock Exchange on October 10, 2022, becoming the first company in Ningbo to do so under the registration system[5]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" enterprise at the national level[44]. - The company was recognized as a "Ningbo Manufacturing Single Champion Demonstration Enterprise" in 2021, highlighting its industry leadership[66]. - The company has established a stable marketing service network with 30 offices nationwide, providing professional support to users[66]. - The company has a comprehensive product line in the life sciences instrument sector, with significant applications in major research institutions and universities[66]. Financial Performance - The company's operating revenue for 2022 was CNY 190,228,158.94, representing a 13.12% increase compared to CNY 168,157,801.62 in 2021[30]. - The net profit attributable to shareholders decreased by 17.21% to CNY 40,080,560.14 from CNY 48,412,472.26 in the previous year[30]. - The total assets increased by 171.17% to CNY 636,611,335.69 at the end of 2022, compared to CNY 234,768,189.49 at the end of 2021[31]. - The company's net assets attributable to shareholders rose by 239.10% to CNY 554,692,967.10 from CNY 163,577,514.61 in 2021[31]. - The basic earnings per share decreased by 24.66% to CNY 0.55 in 2022, down from CNY 0.73 in 2021[30]. - The company's gross profit margin for 2022 was 62.58%, down from 68.27% in 2021[30]. - The company's current ratio improved to 10.78 in 2022, compared to 3.88 in 2021[31]. - The debt-to-asset ratio (consolidated) decreased to 8.94% in 2022 from 21.08% in 2021[31]. - The net cash flow from operating activities for 2022 was ¥69,979,688.21, an increase of 38.35% compared to ¥50,581,456.97 in 2021[32]. Research and Development - The company increased its R&D personnel by 30.56% compared to 2021, enhancing its innovation capabilities[48]. - R&D expenditure for the period amounted to ¥15,980,453.75, accounting for 8.40% of operating income, an increase from 7.45% in the previous year[106]. - The company is developing an automatic microbial growth curve analyzer to improve laboratory efficiency and reduce manual workload[109]. - The company is focusing on developing steam sterilization systems for freeze dryers to comply with new GMP certification requirements, significantly increasing market demand for such equipment[112]. - The company aims to enhance its biological sample processing product line to improve detection sensitivity and accuracy, focusing on automation and integration of single-function instruments[129]. Market and Competition - The company faces significant market competition risks, particularly from internationally renowned scientific instrument manufacturers, which may impact market share and profitability[13]. - The life science instruments industry involves high technical barriers due to the need for advanced technologies such as precision electronics, mechanical engineering, and automation control, requiring significant R&D investment and expertise[59]. - The industry faces a talent barrier as it requires interdisciplinary professionals in fields like biotechnology, chemical analysis, and automation, which are currently in short supply domestically[60]. - The company recognizes the risk of intensified market competition from international brands and the potential impact on market share and profitability[133]. Corporate Governance and Compliance - The company has established a governance structure with three independent directors and strategic and audit committees to enhance management and protect shareholder interests[139]. - The company has maintained compliance with its commitments made during the public offering and there are no violations reported[163]. - The audit report confirmed that there were no non-standard audit opinions, ensuring the integrity of the company's financial reporting[116]. - The company has outlined measures to address any unfulfilled commitments, ensuring accountability[161]. Investment and Capital Management - The company raised a total of RMB 373,889,115 through the issuance of 24,925,941 shares at a price of RMB 15.00 per share[180]. - The company plans to use part of its idle raised funds for cash management, which will not impact the normal progress of investment projects and aims to improve fund utilization efficiency[152]. - The company has not changed the use of raised funds and has complied with all necessary regulations regarding fund management[184]. - The company plans to continue its focus on expanding its marketing network and technical services with the raised funds[183]. Social Responsibility - The company has received a "Excellent" rating in corporate social responsibility evaluations[6]. - The company donated a total of 65,000 CNY to various charitable foundations, including 15,000 CNY to the Ningbo Red Cross and 20,000 CNY to the Ningbo Charity Federation[121].

Financial Performance - The company's operating revenue for 2022 is expected to be ¥190,930,536.43, representing a 13.54% increase compared to the previous year [3]. - The net profit attributable to shareholders is expected to be ¥40,177,056.22, a decrease of 17.01% year-on-year [5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥37,842,737.52, down 14.40% from the previous year [3]. - Basic earnings per share are expected to decline by 23.29% to ¥0.56 [3]. Assets and Equity - Total assets at the end of the reporting period are expected to be ¥636,793,119.52, an increase of 171.24% from the beginning of the period [4]. - Shareholders' equity attributable to the company is expected to reach ¥554,789,463.14, up 239.16% from the beginning of the period [4]. - The total share capital is expected to increase by 37.43% to ¥91,515,941.00 [4]. Factors Affecting Performance - The decline in net profit is primarily due to the impact of recurring COVID-19, changes in product sales structure, and increased R&D expenses [7]. - The company has increased its R&D investment and issued shares to unspecified qualified investors, contributing to the increase in total assets and equity [7]. Cautionary Notes - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks [8].